Fisher to sell Cholestech LDX System in US:
This article was originally published in Clinica
Fisher HealthCare is to distribute Cholestech's LDX System in the US under a multi-year, non-exclusive agreement. Haywood, California-based Cholestech's product, which aids in the detection of cardiovascular disease, is a telephone-sized device that carries out multiple, simultaneous tests from a drop of blood, providing results in under five minutes. The company claims results are as accurate as similar tests conducted in clinical and hospital labs. Fisher HealthCare, a division of Fisher Scientific, plans to distribute the product to over 75,000 acute care and physician office laboratories.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.